US Congressional Research Service Report on Pharmaceutical Supply Chain Security
The Congressional Research Service (CRS) prepares reports for the Members and Committees of the US Congress. On 12 July 2013 they published a report titled “Pharmaceutical Supply Chain Security” that addressed the complexities in the global distribution supply chain for finished drug products.
The complexities are well illustrated and described in Figure 1 (page 6) and a textbox (page 5) respectively. Between the time when a finished drug leaves the manufacturer it may pass through multiple primary and secondary wholesale distributors and often multiple dispensers before actually reaching the patient. This supply chain may also include a re-packager and third party logistics providers including temporary transport companies or warehouse providers. The complexity of the supply chain provides multiple opportunities for adulteration, drug diversion and counterfeiting. This report describes how Congress has moved to regulate the supply chain with details on the following:
• Prescription Drug Marketing Act of 1987
• Amendments to the Food and Drug Act in 2007
• Food and Drug Administration Safety and Innovation Act of 2012
• State Activities on Supply Chain Security
• Actions taken by Professional and Industry Associations
• Policy Decision Points under Consideration in the 113th Congress
To view or download the Congressional Research Service Report, click here
To view or download the Rx-360 Summary of the Report, click here
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...